Search Within

Alan H Shih

  1. "Cancer Biology and Genetics Program Faculty"
Formats
  1. Journal Article (5)
  2. Meeting Abstract (3)
Groups
  1. Adult Leukemia (8)
  2. Cancer Biology and Genetics Program Faculty (8)
  3. Center for Hematologic Malignancies (8)
  4. Department of Medicine (8)
  5. Executive Committee, Center for Hematologic Malignancies (8)
  6. GSK Faculty (8)

More Groups

People
  1. Craig Thompson (8)
  2. Ross Levine (8)
  3. Andrew Intlekofer (5)
  4. Martin Tallman (4)
  5. Omar Abdel-Wahab (4)
  6. Patrick Ward (4)

More People

Years
  1. 2018 (2)
  2. 2017 (2)
  3. 2014 (3)
  4. 2010 (1)
Publications
  1. Blood (3)
  2. Cancer Cell (1)
  3. Cancer Discovery (1)
  4. Cell Reports (1)
  5. Journal of Clinical Investigation (1)
  6. Nature (1)
Publishers
  1. American Society of Hematology (3)
  2. Cell Press (2)
  3. American Association for Cancer Research (1)
  4. American Society for Clinical Investigation (1)
  5. Nature Publishing Group (1)

Results (8)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
    Journal Article

    Intlekofer, A. M.; Shih, A. H.; Wang, B.; Nazir, A.; Rustenburg, A. S.; Albanese, S. K.; Patel, M.; Famulare, C.; Correa, F. M.; Takemoto, N.; more...
    Nature (2018)

    Fulltext@MSK | Save
  • JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition
    Journal Article

    McKenney, A. S.; Lau, A. N.; Hanasoge Somasundara, A. V.; Spitzer, B.; Intlekofer, A. M.; Ahn, J.; Shank, K.; Rapaport, F. T.; Patel, M. A.; Papalexi, E.; more...
    Journal of Clinical Investigation (2018)

    Fulltext@MSK | Save
  • Spliceosomal dysfunction Is a critical mediator of IDH2 mutant leukemogenesis
    Meeting Abstract

    Yoshimi, A.; Lin, K. T.; Wiseman, D.; Intlekofer, A. M.; Wang, B.; Pastore, A.; Rahman, M.; Lee, S. C. W.; Liu, B.; Micol, J. B.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Combination targeted therapy to disrupt aberrant oncogenic signaling and reverse epigenetic dysfunction in IDH2- and TET2-mutant acute myeloid leukemia
    Journal Article

    Shih, A. H.; Meydan, C.; Shank, K.; Garrett-Bakelman, F. E.; Ward, P. S.; Intlekofer, A. M.; Nazir, A.; Stein, E. M.; Knapp, K.; Glass, J.; more...
    Cancer Discovery (2017)

    Fulltext@MSK | Save
  • AG-221, a small molecule mutant IDH2 inhibitor, remodels the epigenetic state of IDH2-mutant cells and induces alterations in self-renewal/differentiation in IDH2-mutant AML model in vivo
    Meeting Abstract

    Shih, A. H.; Shank, K. R.; Meydan, C.; Intlekofer, A. M.; Ward, P.; Thompson, C. B.; Melnick, A. M.; Travins, J.; Straley, K.; Gliser, C.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid lukemia
    Meeting Abstract

    Rampal, R. K.; Alkalin, A.; Madzo, J.; Vasanthakumar, A.; Pronier, E.; Patel, J. P.; Li, Y. S.; Ahn, J.; Abdel-Wahab, O.; Shih, A. H.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia
    Journal Article

    Rampal, R.; Alkalin, A.; Madzo, J.; Vasanthakumar, A.; Pronier, E.; Patel, J.; Li, Y.; Ahn, J.; Abdel-Wahab, O.; Shih, A.; more...
    Cell Reports (2014)

    Fulltext@MSK | Save
  • Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation
    Journal Article

    Figueroa, M. E.; Abdel-Wahab, O.; Lu, C.; Ward, P. S.; Patel, J.; Shih, A.; Li, Y.; Bhagwat, N.; Vasanthakumar, A.; Fernandez, H. F.; more...
    Cancer Cell (2010)

    Fulltext@MSK | Save